An Integrated Approach Towards Development of Highly Specific Chemotherapeutics [ 2005-01-01 - 2008-06-30 ]

Research Grant

Researchers: A/Prof Lawrence Gahan (Chief Investigator) ,  Dr Mark Riley (Chief Investigator) ,  Nicholas Dixon (Chief Investigator) ,  Prof Graeme Hanson (Chief Investigator) ,  Professor Gary Schenk (Chief Investigator)
View all 8 related researchers

Brief description An Integrated Approach Towards Development of Highly Specific Chemotherapeutics. Many diseases are caused or can be treated by modifying the activities of particular enzymes. Molecules that affect enzymatic activities have potential as therapeutic agents. A successful approach to the discovery of new drug molecules is to design them based on very detailed knowledge of how the target enzyme works. In this project, a highly motivated team of scientists will use state of the art instruments and their combined creativity to understand the intimate details of how one large group of enzymes work. The enzymes selected are the bimetallic hydrolases, many of which are associated with disorders including osteoporosis, mental illnesses, cystic fibrosis and various types of cancer.

Funding Amount $420,000

Funding Scheme Discovery Projects

View this grant in the ARC Data Portal